Constipation: pathophysiology and management
|
|
- Nickolas Floyd
- 6 years ago
- Views:
Transcription
1 REVIEW C URRENT OPINION Constipation: pathophysiology and management Arnold Wald Purpose of review Continuing advances in pharmaceutical development are providing an expanding array of treatment approaches for patients with chronic constipation. More comprehensive characterization of pancolonic motility carries the promise of improved understanding of the pathophysiology of this common disorder. Chronic constipation which responds poorly to laxatives may result from the use of drugs such as opioids, or from defecation disorders and advanced colonic dysmotility. Recent findings This article highlights improved characterization of pancolonic motility, evidence of efficacy of established and novel drugs for both idiopathic and opioid-induced constipation and a new algorithm for the evaluation of patients with chronic idiopathic constipation who respond inadequately to available laxatives. Summary The articles cited in this review inform the reader of new developments in the evaluation and treatment of patients with chronic constipation. Keywords colonic motility, constipation, laxatives, opioid antagonists, opioid-induced constipation INTRODUCTION Chronic constipation is a common complaint in all countries and it is presumed, but not proven, that disorders of colonic and/or anorectal function underlie the disorder. The vast majority of patients with constipation is not studied but is treated on an empirical basis with laxatives, which either increase intestinal water content directly or stimulate motility leading to shortened colonic transit and decreased water absorption. This article reviews recent developments in the management of constipation and newer studies that advance our understanding of colonic motility in general. These include advances in characterizing pancolonic motility using high-resolution techniques, updates of newer laxatives and promotility agents for chronic idiopathic constipation (CIC), new approaches to the treatment of opioid-induced constipation (OIC), and a revised algorithm for evaluation of constipation which is unresponsive to standard laxatives. HIGH-RESOLUTION COLONIC MANOMETRY Dinning et al. [1] continue to refine their studies of pancolonic motility with spatiotemporal mapping. Using a new high-resolution fiberoptic manometry system with 72 sensors at 1 cm intervals, they recorded colonic motor activity in 10 healthy individuals when fasted and after a test meal. They identified four types of propagating motor patterns, most of which propagated in a retrograde fashion. Following a meal, the well characterized highamplitude propagating contractions (HAPCs) were accompanied by an increase in retrograde cyclic motor patterns. The authors believe that propagating motor patterns may be generated by two independent sources, potentially of neurogenic or myogenic origin. These studies offer further potential insights into colon physiology in health and constipation. This is not to infer that patients with severe intractable constipation require these studies or that the results of these studies can be used to guide management. Likewise, the wireless motility capsule which records from only a single moving transducer is not likely to illuminate underlying colon motor Division of Gastroenterology and Hepatology, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin, USA Correspondence to Arnold Wald, MD, Professor of Medicine, Division of Gastroenterology and Hepatology, University of Wisconsin School of Medicine and Public Health, Centennial Building, 4th floor, 1685 Highland Avenue, Madison, WI 53705, USA. Tel: ; fax: ; axw@medicine.wisc.edu Curr Opin Gastroenterol 2015, 31:45 49 DOI: /MOG ß 2014 Wolters Kluwer Health Lippincott Williams & Wilkins
2 Large intestine KEY POINTS The development of peripherally restricted m-opiate receptor antagonists represents a major advancement in the treatment of opioid-induced constipation. The demonstration of noninferiority of PEG-electrolyte vs. a high-affinity 5-hydroxytryptamine4 (5-HT4) agonist reaffirms the desirability of studies to compare new laxatives with established and inexpensive laxatives such as bisacodyl and polyethylene glycol to help guide laxative use in chronic idiopathic constipation (CIC). Novel secretory drugs and high-affinity 5-HT4 agonists currently remain a second tier choice for CIC, but may have a more primary role in irritable bowel syndrome with constipation. Patients with CIC refractory to available laxatives should be tested for a defecation disorder using both balloon expulsion and anorectal manometry before measuring colonic transit times. patterns. There has been a declining interest in the wireless capsule which provides no more information than do widely available radiopaque markers to measure whole-gut and colonic transit. PHARMACOLOGICAL AGENTS FOR CONSTIPATION The medical management of CIC continues to be suboptimal, with many patients expressing dissatisfaction with conventional therapies. As CIC is a symptom-based disorder, it is unclear whether this dissatisfaction is based on psychosocial or biologic factors, or both. Nevertheless, there continues to be a resurgence of interest in drugs that stimulate gastrointestinal motility through the 5-hydroxytryptamine4(5-HT4) receptor, as well as through other novel mechanisms. There is a lengthy published record on the efficacy of prucalopride for CIC, as summarized in a meta-analysis published in 2011 [2]. Prucalopride is a high-affinity 5-HT4 receptor agonist, which is known to stimulate gastrointestinal motility. The drug has yet to be approved for use in the United States, although it is widely used in Europe. A recent publication [3] demonstrated the efficacy of prucalopride 2 mg daily in a randomized controlled study involving 358 men (38% achieved the primary endpoint vs. 18% placebo controls over a 12-week treatment period). This extends and confirms previous studies of prucalopride on women with CIC. A potentially more important study compared prucalopride with 26 g of polyethylene glycol (PEG)- electrolyte administered as a split dose for 4 weeks in a noninferiority analysis [4 & ]. With 120 patients in each treatment arm and more than 99% compliance with therapy, the proportion of patients achieving the primary endpoint of more than three complete and spontaneous bowel movements (SBM) in the last week of therapy was higher with PEG (67 vs. 57%), as was the proportion of patients achieving secondary endpoints. In an accompanying editorial, Ford [5 & ] raised the provocative issue of whether future studies in CIC should continue to be placebo controlled or should include a comparator group consisting of one of the effective but inexpensive laxatives such as PEG or bisacodyl. As we attempt to control healthcare costs, comparator studies will be important in deciding which new drugs should be available as first-line agents to most patients with CIC. SECRETORY AGENTS Lubiprostone and linaclotide are available for CIC and irritable bowel syndrome with constipation (IBS-C). A recent systematic review identified three randomized placebo-controlled studies of linaclotide in IBS-C encompassing 1773 patients [6]. Their conclusion was that there was moderate confidence that linaclotide is moderately effective compared to placebo for improving typical symptoms of IBS-C. Linaclotide was estimated to reduce the number of failures to achieve symptom relief by 165/1000 patients, although this gain was offset by the need to discontinue therapy because of diarrhea in 31/1000 patients. Plecanatide is another secretory agent similar to linaclotide and also works as an agonist of the GC-C receptors, uroguanylin and guanylin, to activate guanylate cyclase C. This increases intestinal secretion of chloride via the cystic fibrosis transmembrane conductance regulator pump. Early studies suggest that plecanatide, similar to linaclotide, may be effective for CIC and also IBS-C and may improve abdominal pain independent of stool frequency. The first human study to be published used nine different doses in healthy controls; there was minimal, if any, drug absorption, the incidence of diarrhea was not different from placebo, and increased side-effects occurred only at high doses [7]. A preliminary phase 2a study showed impressive and beneficial improvement in all categories of constipation and Bristol stool form scores with benefit plateauing at the 1 mg dose [8]. It is likely that secretory agents will remain a second tier option for CIC but may have a more prominent role in IBS-C for which there are fewer alternatives to treatment Volume 31 Number 1 January 2015
3 Consti pation: pathophysiology and management Wald OSMOTIC AGENTS It is always reassuring when inexpensive and traditional treatments are validated in well controlled randomized trials. This is illustrated by a recent study of the efficacy of a magnesium sulfaterich natural mineral water in women with CIC. This product (known as Hépar) has been marketed in France since 1930 [9] and contains magnesium 119 mg/l and sulfate 1550 mg/l, among others. The daily consumption of 1 l Hépar-reduced constipation over a 4 week period by 37.5 vs. 21% for those consuming 1 l of a low mineral natural water; there were no serious side-effects. Previous studies in children had shown that high doses of magnesium sulfate (>2000 mg/day) were as efficacious as PEG to improve frequency and consistency of stools [10]. This product would appear to be a possible first tier option for constipation in addition to stimulant laxatives and PEG. OPIOID-INDUCED CONSTIPATION An excellent review on the subject of constipation induced by opioids highlighted the dramatic increase in the use of opiates and opioids for chronic pain over the past two decades [11]. An estimated 40 90% of patients who use opioids have constipation and other gastrointestinal side-effects [12 && ]. Opioids delay gastrointestinal transit, stimulate nonpropulsive motor activity, increase intestinal tone, increase fluid absorption by prolonging contract time for absorption to occur and decrease secretion of electrolytes and water into the intestinal lumen. A recent systematic review of treatment for OIC concluded that three different m-opioid receptor antagonists methylnaltrexone (six trials, 1610 patients), naloxone (four trials, 798 patients) and almivopam (four trials, 1693 patients) were all superior to placebo for OIC [13]. Currently, the use of methylnaltrexone is restricted by the need for subcutaneous injection only in patients with medically advanced illness, whereas almivopam is indicated only to shorten the duration of postoperative ileus [12 && ]. Chronic use of naloxone alone has not been approved for use in the United States. Recent studies support the use of three additional pharmacologic agents in the treatment of OIC; two include peripherally restricted m-opiate receptor antagonists, whereas the third is the intestinal secretory agent, lubiprostone. A recently published study supports the efficacy of lubiprostone to treat OIC in patients with chronic pain that is not attributable to cancer [14]. In a multicenter randomized, placebo-controlled trial, 210 patients with OIC were given lubiprostone 24 mg twice daily and 208 patients were given a placebo over a 3-month trial period. Approximately two-thirds of patients in each arm completed the trial and the primary endpoint was the change in SBM frequency at week 8 compared with baseline. Mean changes were approximately one SBM/week higher in patients treated with lubiprostone compared with placebo; this was statistically significant at 8 weeks but not at 12 weeks because there were fewer patients analyzed at 12 weeks. Statistically significant changes with lubiprostone were also seen in stool consistency, severity of constipation, straining and abdominal discomfort, but not bloating or bowel regularity. Overall effectiveness was rated as slightly but significantly higher by patients taking drug vs. placebo (mean was about 0.4 higher than placebo on a 0 4 scale, wherein 0 was not effective and 4 was extremely effective). The percentage of patients in each group who achieved the primary endpoint was not provided. Nausea occurred in 16.8% of patients (5.8% placebo), diarrhea in 9.6% (2.9% placebo), and abdominal distension in 8.2% (2.4% placebo), all statistically significant. A more biologically plausible approach to OIC is to combine a strong opiate agent with an effective opioid receptor antagonist which will not counteract the benefits of pain reduction. An example of this is oxycodone/naloxone. Naloxone is an opioid receptor antagonist that exhibits a local effect on GI opioid receptors but is nearly completely inactivated by the liver after oral administration. A timely review that summarized the use of oxycodone/naloxone in patients with chronic pain (nonmalignant pain and cancer-related pain) was recently published [15]. An initial dose of 10/5 mg or 20/10 mg twice daily is often effective and the drug is titrated to a maximum of 40/20 mg twice daily with the goal of achieving effective analgesia and acceptable adverse effects. The FDA has just approved an extendedrelease formulation of oxycodone/naloxone (Targuiniq ER, Purdue Pharma LP, Stamford, Connecticut, USA) as an abuse deterrent agent for use in pain severe enough to require daily, around the clock, long-term opioid treatment, for which alternative treatment options are inadequate. A variation on this theme is the development of naloxegol, a pegylated derivative of naloxone, which limits the ability of naloxegol to cross the blood brain barrier so that it acts only on peripheral m-opioid receptors. In a phase 2, randomized, double-blind controlled trial that tested doses of 5 mg, 25 mg, and 50 mg given once daily, statistically significant increases in SBM per week were observed for the two higher doses vs. placebo [16]. Adverse effects were increased in patients receiving 50 mg daily but most adverse effects with the 5 mg ß 2014 Wolters Kluwer Health Lippincott Williams & Wilkins 47
4 Large intestine and 25 mg doses were mild and transient. On the basis of these studies, two identical randomized, controlled, phase 3 studies consisting of 1352 patients were performed with patients receiving 12.5 mg or 25 mg daily vs. placebo over a 3-month period [12 && ]. The primary endpoint was the 12-week response rate (3 SBM per week plus an increase from baseline of 1 SBM for 9 of 12 weeks and for 3 of the final 4 weeks). Two populations were analyzed: all patients, in an intention to treat model, and only patients with an inadequate previous response to laxatives. Response rates to the 25 mg dose in both studies were statistically significantly higher than placebo (44.4 vs. 29.4%; 39.7 vs. 29.3%) with numbers needed to treat of 6.7 and 9.7, respectively. This was also true for the subpopulation with an inadequate response to laxatives (48.7 vs. 28.8%; 46.8 vs. 31.4%; numbers needed to treat of 5.0 and 6.5, respectively). Mean daily opioid doses remained stable during both studies and adverse effects were infrequent, the most frequent being abdominal pain in both studies (12.6 and 19.0% vs. 3.3 and 7.8% for placebo, respectively). DEFECATION DISORDERS Many patients with severe intractable constipation have either a defecatory disorder, known as dyssynergic defecation or isolated slow transit constipation, known as colonic inertia. The classical diagnostic approach to such patients has been to perform both colonic transit using radiopaque markers, and anorectal manometry (ARM) (or electromyography) with balloon expulsion. A recent technical review proposes a shift in the algorithm for diagnostic testing [17 && ]; another study confirms the validity of the balloon expulsion test (BET) [18]. The new technical review on constipation released by the American Gastroenterological Association suggests that patients with intractable constipation should initially undergo ARM and the BET, without a colon transit study [17 && ]. There were two reasons advanced for this position. First, up to 50% of patients with dyssynergic defecation have slow colonic transit, many of whom will normalize after successful treatment of the dyssynergic defecation. If initial testing is normal or if patients normalize the dyssynergic pattern with biofeedback but symptoms persist, a colon transit study should be performed to identify patients with slow transit. If patients with dyssynergic defecation respond clinically to biofeedback, colon transit testing is not necessary. This presumes that there are experienced laboratories that perform both studies when evaluating these patients. Unfortunately, no single test is sufficiently definitive to make a diagnosis of dyssynergic defecation. A recent study was designed to test the reproducibility and agreement of the BET with ARM or EMG [18]. In a single center, 286 consecutive patients with chronic constipation and 40 healthy controls underwent BET on two occasions less than 1 month apart. Patients also underwent ARM and EMG; 47 patients with conflicting manometry and BETs underwent defecography. All healthy controls passed a 50 ml water-filled balloon within two minutes (93% within 1 min), with perfect reproducibility, thus establishing the upper limit of normal. One hundred and forty-five patients had a normal BET and 141 were abnormal, also with perfect reproducibility. The level of agreement between BET and manometry was 78% and between BET and EMG was 83%. Thus, the BET is an office-based procedure, which is a reliable first test for dyssynergic defecation; if abnormal, ARM and/or defecography can be used to determine why expulsion is abnormal in a patient with chronic refractory constipation. Balloon expulsion alone or manometry alone is insufficient to evaluate a patient with suspected dyssynergic defecation. CONCLUSION The most recent therapeutic advances in chronic constipation are for the treatment of OIC, with the recent release of a combined opiate/opiate antagonist, the development of a pegylated opiate antagonist, and evidence of efficacy for lubiprostone. Although a number of new laxatives have shown efficacy for CIC, the demonstration of noninferiority of an inexpensive laxative vs. prucalopride underscores the need for more comparator studies of new and expensive drugs vs. effective, inexpensive laxatives such as bisacodyl and PEG. This will guide laxative use in CIC and help to better manage healthcare expenditures. The demonstration of efficacy of a magnesium sulfate rich natural mineral water in women with CIC demonstrates that newer and more expensive treatments are not necessarily better than older and inexpensive remedies for this very frequent condition. Acknowledgements Financial support and sponsorship Conflicts of interest A.W. has served as a consultant to the following companies: Forest Lab, Ironwood, Takeda/Sucampo Volume 31 Number 1 January 2015
5 Consti pation: pathophysiology and management Wald REFERENCES AND RECOMMENDED READING Papers of particular interest, published within the annual period of review, have been highlighted as: & of special interest && of outstanding interest 1. Dinning PG, Wiklendt L, Maslen L, et al. Quantification of in vivo colonic motor patterns in healthy humans before and after a meal revealed by high resolution fiber optic manometry. Neurogastroenterol Motil 2014; 26: Shin A, Camilleri M, Kolar G, et al. Systematic review with meta-analysis: highly selective 5-HT4 agonists (prucalopride, velusetrag or naronapride) in chronic constipation. Aliment Pharmacol Ther 2014; 39: Yiannakou Y, Bouchoucha M, Schiefke I, et al. Efficacy and safety of prucalopride in men with chronic constipation: a phase 3 randomized, double blind, placebo controlled trial. Gastroenterology 2014; 146:A & Cinca R, Chera D, Gruss HJ, Halphen M. Randomised clinical trial: macrogol/ PEG 3350þelectrolytes versus prucalopride in the treatment of chronic constipation a comparison in a controlled environment. Aliment Pharmacol Ther 2013; 37: An important study showing noninferiority (and perhaps superiority) of an established inexpensive laxative to a new 5HT4 agonist which is as yet not available in the United States. Newer is not always better but is invariably more expensive. 5. & Ford AC. Death knell for placebo-controlled trials in chronic idiopathic constipation? Gastroenterology 2013; 145: A succinct provocative editorial commenting on reference (Cinca) advocating the need for future comparator studies of new agents for constipation with established effective laxatives. 6. Atluri DK, Chandar AK, Bharucha AE, Falck-Ytter Y. Effect of linaclotide in irritable bowel syndrome with constipation (IBS-C): a systematic review and meta-analysis. Neurogastroenterol Motil 2014; 26: Shailubhai K, Comiskey S, Foss JA, et al. Plecanatide, an oral guanylate cyclase C agonist acting locally in the gastrointestinal tract, is safe and well tolerated in single doses. Dig Dis Sci 2013; 58: Quigley EM. Open channels for functional bowel disorders: guanylate cyclase C agonists in IBS and CC. Dig Dis Sci 2013; 58: Dupont C, Campagne A, Constant F. Efficacy and safety of a magnesium sulfate-rich natural mineral water for patients with functional constipation. Clin Gastroenterol Hepatol 2014; 12: Gomes PB, Duarte MA, Melo Mdo C. Comparison of the effectiveness of polyethylene glycol 4000 without electrolytes and magnesium hydroxide in the treatment of chronic functional constipation in children. J Pediatr (Rio J) 2011; 87: Camilleri M. Opioid induced constipation: challenges and therapeutic opportunities. Am J Gastroenterol 2011; 106: && Chey WD, Webster L, Sostek M, et al. Naloxegol for opioid-induced constipation in patients with noncancer pain. N Engl J Med 2014; 370: This article and its companion study [16] provide data to support this novel peripheral m-opioid receptor antagonist to treat OIC. 13. Ford AC, Brenner DM, Schoenfeld PS. Efficacy of pharmacological therapies for the treatment of opioid-induced constipation: systematic review and metaanalysis. Am J Gastroenterol 2013; 108: Cryer B, Katz S, Vallejo R, et al. A randomized study of lubiprostone for opioidinduced constipation in patients with chronic noncancer pain. Pain Med [Epub ahead of print] 15. Leppert W. Oxycodone/naloxone in the management of patients with pain and opioid-induced bowel dysfunction. Curr Drug Targets 2014; 15: Webster L, Dhar S, Eldon M, et al. A phase 2, double-blind, randomized, placebo-controlled, dose-escalation study to evaluate the efficacy, safety, and tolerability of naloxegol in patients with opioid-induced constipation. Pain 2013; 154: && Bharucha AE, Pemberton JH, Locke lll GR. American Gastroenterological Association technical review on constipation. Gastroenterology 2013; 144: This is the most recent evidence-based comprehensive review on this subject. 18. Chiarioni G, Kim SM, Vantini I, et al. Validation of the balloon evacuation test: reproducibility and agreement with findings from anorectal manometry and electromyography. Clin Gastroenterol Hepatol [Epub ahead of print] ß 2014 Wolters Kluwer Health Lippincott Williams & Wilkins 49
daily; available as 10- mg g PO
Overview of the PRN: The Pain and Palliative Care PRN of ACCP is an organization of pharmacy practitioners, clinical scientists, pharmacy educators, and others. Its mission is to advance pain and palliative
More informationOCTOBER 7-10 PHILADELPHIA, PENNSYLVANIA
OMED 17 OCTOBER 7-10 PHILADELPHIA, PENNSYLVANIA 29.5 Category 1-A CME credits anticipated ACOFP / AOA s 122 nd Annual Osteopathic Medical Conference & Exposition Joint Session with ACOFP and Cleveland
More informationEvidence-based Treatment Strategies for
Evidence-based Treatment Strategies for Chronic Constipation William D. Chey, MD Professor of Medicine University of Michigan Rome III criteria*: Chronic constipation Must include 2 of the following (>25%
More informationOPIOID-INDUCED CONSTIPATION DR ANDREW DAVIES
OPIOID-INDUCED CONSTIPATION DR ANDREW DAVIES Introduction Introduction Mean faecal weight 128 g / cap / day Mean range 51-796 g Absolute range 15-1505 g Main factors affecting mass are caloric intake,
More informationAmitiza. Amitiza (lubiprostone) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.50.22 Subject: Amitiza Page: 1 of 5 Last Review Date: March 16, 2018 Amitiza Description Amitiza (lubiprostone)
More informationOpioid-Induced Constipation
Objectives Opioid-Induced Constipation Brianna Jansma, PharmD Alex Smith, PharmD Megan Robinson, PharmD Summarize epidemiology of opioid-induced constipation (OIC) Understand opiates effects on the gastrointestinal
More informationSlide #43. Functional Disorders - An Update 11/8/ MA ACP Annual Scientific Meeting. Functional Disorders: An Update
Functional Disorders: An Update Anthony Lembo, M.D. Associate Professor of Medicine Beth Israel Deaconess Medical Center Harvard Medical School Boston, MA Disclosure of Financial Relationships Anthony
More informationEmerging Treatments for IBS-C and Clinical Trial Endpoints
Emerging Treatments for IBS-C and Clinical Trial Endpoints Lin Chang, M.D. Oppenheimer Family Center for Neurobiology of Stress David Geffen School of Medicine at UCLA Learning Objectives Describe current
More informationElderly Man With Chronic Constipation
Elderly Man With Chronic Constipation Linda Nguyen, MD Director, Neurogastroenterology and Motility Clinical Assistant Professor Stanford University Overview Normal bowel function Defining Constipation:
More informationIRONWOOD AND FOREST ANNOUNCE POSITIVE LINACLOTIDE RESULTS FROM PHASE 3 TRIAL IN PATIENTS WITH IRRITABLE BOWEL SYNDROME WITH CONSTIPATION
FOR IMMEDIATE RELEASE Ironwood Contact: Forest Contact: Susan Brady Frank J. Murdolo Corporate Communications Vice President, Investor Relations 617.621.8304 212.224.6714 sbrady@ironwoodpharma.com frank.murdolo@frx.com
More informationUBS Global Healthcare Conference May 19, 2014
UBS Global Healthcare Conference May 19, 2014 Safe Harbor Statement This presentation may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section
More informationPharmacotherapy for IBS
Pharmacotherapy for IBS Brooks D. Cash, M.D., FACG Chief, Gastroenterology Professor of Medicine University of South Alabama Director, GI Physiology, USA Medical Center Mobile, AL Disclosures I have served
More informationChronic constipation in the elderly
Chronic constipation in the elderly 1 Dec,2011 R 2 Natta Asanaleykha Epidemiology Definition Scope The impact of chronic constipation in the elderly Pathophysiology Evaluation the elderly patient with
More informationSynergy Pharmaceuticals TRULANCE (Plecanatide) Receives U.S. FDA Approval for the Treatment of Adults with Chronic Idiopathic Constipation
January 19, 2017 Synergy Pharmaceuticals TRULANCE (Plecanatide) Receives U.S. FDA Approval for the Treatment of Adults with Chronic Idiopathic Constipation NEW YORK--(BUSINESS WIRE)-- Synergy Pharmaceuticals
More informationEfficacy and Safety of Lubiprostone. Laura Wozniak February 23, 2010 K30 Monthly Journal Club
Efficacy and Safety of Lubiprostone Laura Wozniak February 23, 2010 K30 Monthly Journal Club Objectives Brief overview of constipation Review of article Discussion Constipation in Children 3-5% of all
More informationAdvancing gastroenterology, improving patient care
American College of Gastroenterology Advancing gastroenterology, improving patient care Note to Visitors: A fully updated ACG Systematic Review on the Management of Chronic Idiopathic Constipation and
More information10/10/16. Disclosures. Educational Objectives
Nimish Vakil, MD, FACP, FACG, AGAF, FASGE Clinical Adjunct Professor University of Wisconsin Madison, Wisconsin Disclosures All faculty, course directors, planning committee, content reviewers and others
More informationMANAGEMENT OF CHRONIC CONSTIPATION BEYOND LAXATIVES
Enrique Rey Professor of Medicine Head. Department of Digestive Diseases Hospital Clínico San Carlos Complutense University Madrid, Spain MANAGEMENT OF CHRONIC CONSTIPATION BEYOND LAXATIVES CONSTIPATION:
More informationA 27-Year-Old Woman With Constipation: Diagnosis and Treatment
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY 2010;8:838 842 EDUCATION PRACTICE A 27-Year-Old Woman With Constipation: Diagnosis and Treatment ARNOLD WALD Section of Gastroenterology and Hepatology, University
More informationChildhood constipation, a real problem..? Marc Benninga, Emma Children s Hospital, AMC, Amsterdam, the Netherlands
Childhood constipation, a real problem..? Marc Benninga, Emma Children s Hospital, AMC, Amsterdam, the Netherlands Constipation 0-10% >10-20% >20-30% >30-40% Mugie SM, et al. Best Pract & Res Clin Gastroenterol
More informationCENTENE PHARMACY AND THERAPEUTICS DRUG REVIEW 2Q17 April May
BRAND NAME Trulance GENERIC NAME Plecanatide MANUFACTURER Synergy Pharmaceuticals, Inc. DATE OF APPROVAL January 19, 2017 PRODUCT LAUNCH DATE Anticipated in 1Q2017 REVIEW TYPE Review type 1 (RT1): New
More informationCENTENE PHARMACY AND THERAPEUTICS DRUG REVIEW 3Q17 July August
BRAND NAME Symproic GENERIC NAME Naldemedine MANUFACTURER Shionogi Inc. DATE OF APPROVAL March 23, 2017 PRODUCT LAUNCH DATE Anticipated to launch mid-summer 2017 REVIEW TYPE Review type 1 (RT1): New Drug
More informationMovantik (naloxegol), Relistor (methylnaltrexone bromide), Symproic (naldemedine)
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.50.06 Subject: Opioid Antagonist Drug Class Page: 1 of 7 Last Review Date: November 30, 2018 Opioid Antagonist
More informationSYMPROIC (naldemedine tosylate) oral capsule
SYMPROIC (naldemedine tosylate) oral capsule Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific benefit plan. This
More informationXifaxan, Lotronex and Viberzi Prior Authorization and Quantity Limit Program Summary
Xifaxan, Lotronex and Viberzi Prior Authorization and Quantity Limit Program Summary FDA APPROVED INDICATIONS DOSAGE 1,2 Lotronex (alosetron) a Indication For women with severe diarrheapredominant irritable
More informationConstipation an Old Friend. Presented by Dr. Keith Harris
Constipation an Old Friend Presented by Dr. Keith Harris Irregularity and the Tricks of the Trade." CONSTIPATION What is constipation? INFREQUENT BOWEL MOVEMENTS DIFFICULTY DURING DEFECATION SENSATION
More informationIrritable Bowel Syndrome Now. George M. Logan, MD Friday, May 5, :35 4:05 PM
Irritable Bowel Syndrome Now George M. Logan, MD Friday, May 5, 2017 3:35 4:05 PM Dr. Logan indicated no potential conflict of interest to this presentation. He does not intend to discuss any unapproved/investigative
More informationEffects of baseline abdominal pain and bloating on response to lubiprostone in patients with irritable bowel syndrome with constipation
Alimentary Pharmacology and Therapeutics Effects of baseline abdominal pain and bloating on response to lubiprostone in patients with irritable bowel syndrome with constipation L. Chang*, W. D. Chey, D.
More informationALVIMOPAN 0.0 OVERVIEW
ALVIMOPAN 0.0 OVERVIEW A. Alvimopan is a peripherally restricted mu-opioid receptor antagonist. B. DOSING INFORMATION : For the treatment of opioid bowel dysfunction, oral alvimopan doses between 0.5 milligrams
More informationFOOT OFF THE BRAKES. Kerri Novak MD MSc FRCPC. Chronic Constipation: Taking the Foot off the Brakes Dr. Kerri Novak
CHRONIC CONSTIPATION: TAKING THE FOOT OFF THE BRAKES Kerri Novak MD MSc FRCPC www.seacourses.com 1 OUTLINE Epidemiology i Quality of life Approach Therapies www.seacourses.com 2 DEFINING CHRONIC CONSTIPATION
More informationMovantik (naloxegol), Relistor (methylnaltrexone bromide)
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.50.06 Subject: Opioid Antagonist Drug Class Page: 1 of 5 Last Review Date: December 2, 2016 Opioid Antagonist
More informationAntidiarrheals Antidiarrheal
Antidiarrheals Major factors in diarrhea Increased motility of the GI tract. Decreased absorption of fluid. Antidiarrheal drugs include: Antimotility agents. Adsorbents. Drugs that modify fluid and electrolyte
More informationOpioid Use in Palliative Care
Opioid Use in Palliative Care Relief of pain is one of the core components of palliative care 1,2 Up to 69% of patients with advanced cancer experience pain 3 ~65% of patients dying from nonmalignant disease
More informationUnderstanding & Alleviating Constipation. Living (Well!) with Gastroparesis Program Warm-Up Class
Understanding & Alleviating Constipation Living (Well!) with Gastroparesis Program Warm-Up Class Please Remember The information presented is for educational purposes only and is in no way intended as
More informationWARNING: RISK OF SERIOUS DEHYDRATION IN PEDIATRIC PATIENTS
June 5, 2018 Synergy Pharmaceuticals Highlights New Data at Digestive Disease Week (DDW) 2018 Linking Uroguanylin Deficiency to Chronic Idiopathic Constipation (CIC) and Irritable Bowel Syndrome with Constipation
More informationNuove terapie per il trattamento della stipsi
Nuove terapie per il trattamento della stipsi Roberto De Giorgio DIMEC, Dipartimento di Scienze Mediche e Chirurgiche, Università di Bologna 1088-2015 Un caso di gonfiore addominale F, 39 aa, BMI 18 -
More informationThe Opportunity: c-ibs and pain relief with confidence YKP10811
The Opportunity: c-ibs and pain relief with confidence YKP10811 1 TABLE OF CONTENTS Profile Summary Clinical Data Mode of Action Pharmacologic Profile Safety and Toxicity Profile ADME Overview vs. Competitors
More informationROME IV CRITERIA FOR IBS
PRACTICAL CONSIDERATIONS IN THE MANAGEMENT OF IBS BRENDA HORWITZ MD PROFESSOR OF CLINICAL MEDICINE LEWIS KATZ SCHOOL OF MEDICINE AND TEMPLE UNIVERSITY HEALTH SCIENCES CENTER OR THINGS I ALWAYS WANTED TO
More informationLinaclotide: A new drug for the treatment of chronic constipation and irritable bowel syndrome with constipation
Review Article Linaclotide: A new drug for the treatment of chronic constipation and irritable bowel syndrome with constipation United European Gastroenterology Journal 1(1) 7 20! Author(s) 2013 Reprints
More informationIrritable Bowel Syndrome. Mustafa Giaffer March 2017
Irritable Bowel Syndrome Mustafa Giaffer March 2017 Introduction First described in 1771. 50% of patients present
More informationComparison of strategies and goals for treatment of chronic constipation among gastroenterologists and general practitioners
ORIGINAL ARTICLE Annals of Gastroenterology (18) 31, 1-6 Comparison of strategies and goals for treatment of chronic constipation among gastroenterologists and general practitioners Dan Carter a,c, Eytan
More informationLinaclotide, Novel Therapy for the Treatment of Chronic Idiopathic Constipation and Constipation-Predominant Irritable Bowel Syndrome
Adv Ther (2013) 30(3):203 11. DOI 10.1007/s12325-013-0012-9 REVIEW Linaclotide, Novel Therapy for the Treatment of Chronic Idiopathic Constipation and Constipation-Predominant Irritable Bowel Syndrome
More informationMovantik (naloxegol), Relistor (methylnaltrexone bromide), Symproic (naldemedine)
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.50.06 Subject: Opioid Antagonist Drug Class Page: 1 of 5 Last Review Date: June 22, 2017 Opioid Antagonist
More informationROME Update from DDW and ACG 2014
ROME Update from DDW and ACG 2014 1 Rome Faculty Douglas Drossman, MD University of North Carolina Chapel Hill, NC Lin Chang, MD David Geffen School of Medicine at UCLA Los Angeles, CA 2 This Program is
More informationBiofeedback for Pelvic Floor Disorders and Incontinence
The UNC Center for Functional GI & Motility Disorders www.med.unc.edu/ibs Biofeedback for Pelvic Floor Disorders and Incontinence Olafur S. Palsson, Psy.D. Associate Professor of Medicine UNC Center for
More informationThe Road to Opioid-Induced Constipation: Pathophysiology and Impact Kenneth C. Jackson, II, PharmD, CPE
Disclaimer This slide deck in its original and unaltered format is for educational purposes and is current as of March 2015. The content and views presented in this educational activity are those of the
More informationEfficacy of Linaclotide for Patients With Chronic Constipation
GASTROENTEROLOGY 2010;138:886 895 Efficacy of Linaclotide for Patients With Chronic Constipation ANTHONY J. LEMBO,* CAROLINE B. KURTZ, JAMES E. MACDOUGALL, B. J. LAVINS, MARK G. CURRIE, DONALD A. FITCH,
More informationDavid Leff, DO. April 13, Disclosure. I have the following financial relationships to disclosure:
David Leff, DO AOMA 94 th Annual Convention April 13, 2016 Disclosure I have the following financial relationships to disclosure: Speaker s Bureau: Allergan Labs, Takeda Pharmaceutical, Valeant Pharmaceutical
More informationALMIRALL AND IRONWOOD ANNOUNCE POSITIVE RESULTS FROM A PHASE 3 TRIAL WITH LINACLOTIDE IN PATIENTS WITH IRRITABLE BOWEL SYNDROME WITH CONSTIPATION
FOR IMMEDIATE RELEASE Ironwood Contact: Almirall Contact: Susan Brady Ketchum Pleon Corporate Communications Amanda Sefton 617.621.8304 +44 (0) 207.611.3653 sbrady@ironwoodpharma.com amanda.sefton@ketchumpleon.com
More informationOpioid constipation treatment dulcolax
P ford residence southampton, ny Opioid constipation treatment dulcolax Posts about how to relieve constipation instantly written by gbrese1958. Official Web site for MOVANTIK (naloxegol) tablets, for
More informationWhat Is Constipation?
CONSTIPATION What Is Constipation? Constipation is when you have infrequent or hard-to-pass bowel movements (meaning they are painful or you have to strain), have hard stools or feel like your bowel movements
More informationDisorders in which symptoms cannot be explained by the presence of structural or tissue abnormalities Irritable bowel syndrome Functional heartburn Functional dyspepsia Functional constipation Functional
More informationIs one of the most common chronic disorders. causing patients to seek medical treatment.
ILOs After this lecture you should be able to : Define IBS Identify causes and risk factors of IBS Determine the appropriate therapeutic options for IBS Is one of the most common chronic disorders causing
More informationWilliam Chey, MD University of Michigan Ann Arbor, MI
Lin Chang, MD David Geffen School of Medicine at UCLA Los Angeles, CA William Chey, MD University of Michigan Ann Arbor, MI Mark Pimentel, MD Cedars-Sinai Medical Center Los Angeles, CA Accredited by Jointly
More informationCurrent and Emerging Pharmacological Treatments in Irritable Bowel Syndrome
Current and Emerging Pharmacological Treatments in Irritable Bowel Syndrome Anthony Lembo, M.D. Associate Professor of Medicine Beth Israel Deaconess Medical Center Harvard Medical School What is the general
More informationTechnology appraisal guidance Published: 23 July 2014 nice.org.uk/guidance/ta318
Lubiprostone for treating chronic idiopathic constipation Technology appraisal guidance Published: 23 July 2014 nice.org.uk/guidance/ta318 NICE 2017. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-ofrights).
More informationACG Clinical Guideline: Management of Benign Anorectal Disorders
ACG Clinical Guideline: Management of Benign Anorectal Disorders Arnold Wald, MD, MACG 1, Adil E. Bharucha, MBBS, MD 2, Bard C. Cosman, MD, MPH, FASCRS 3 and William E. Whitehead, PhD, MACG 4 1 Division
More informationMOVICOL Launched in Japan -The First Polyethylene Glycol Preparation for Chronic Constipation in Japan-
November 29, 2018 EA Pharma Co., Ltd. Eisai Co., Ltd. Mochida Pharmaceutical Co., Ltd. MOVICOL Launched in Japan -The First Polyethylene Glycol Preparation for Chronic Constipation in Japan- EA Pharma
More informationIn the evaluation and management of chronic
HOW TO IDENTIFY, COUNSEL, AND TREAT PATIENTS WITH CHRONIC CONSTIPATION AND IRRITABLE BOWEL SYNDROME * Anthony J. Lembo, MD ABSTRACT Though not a life-threatening condition, chronic constipation has a substantial
More informationOIC, opioid-induced constipation.
Disclosures Charles E. Argoff, MD Speakers Bureau for Allergan, Inc., AstraZeneca plc, Depomed, Inc., Iroko Pharmaceuticals LLC, Janssen Pharmaceuticals, Inc., Millenium Laboratories, and Xenoport Inc.
More informationDisclosures. GI Motility Disorders. Gastrointestinal Motility Disorders & Irritable Bowel Syndrome
Gastrointestinal Motility Disorders & Irritable Bowel Syndrome None Disclosures Jasmine Zia, MD Acting Assistant Professor Division of Gastroenterology, University of Washington 6 th Asian Health Symposium
More informationClass Review: Drugs for Constipation
Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35 Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119
More informationUNDERSTANDING IBS AND CC Implications for diagnosis and management
UNDERSTANDING IBS AND CC Implications for diagnosis and management J. TACK, M.D., Ph.D. Department of Gastroenterology University Hospitals, K.U. Leuven Leuven, Belgium TYPES OF GASTROINTESTINAL DISORDERS
More informationCurrent Pharmacological Treatment Options in Chronic Constipation and IBS with Constipation
Current Pharmacological Treatment Options in Chronic Constipation and IBS with Constipation Anthony Lembo, M.D. Associate Professor of Medicine Harvard Medical School Director, GI Motility Center Beth
More informationMedical Policy. MP Ingestible ph and Pressure Capsule
Medical Policy BCBSA Ref. Policy: 2.01.81 Last Review: 11/15/2018 Effective Date: 11/15/2018 Section: Medicine Related Policies 2.01.20 Esophageal ph Monitoring 6.01.33 Wireless Capsule Endoscopy as a
More informationIBS Irritable Bowel syndrome Therapeutics II PHCL 430
Salman Bin AbdulAziz University College Of Pharmacy IBS Irritable Bowel syndrome Therapeutics II PHCL 430 Email:- ahmedadel.pharmd@gmail.com Ahmed A AlAmer PharmD R.S is 32-year-old woman experiences intermittent
More informationDiagnosis and Management of Irritable Bowel Syndrome (IBS) For the Primary Care Provider
Diagnosis and Management of Irritable Bowel Syndrome (IBS) For the Primary Care Provider Elizabeth Coss, MD General Gastroenterologist Audie Murphy Veterans Hospital UT Health This presentation does not
More informationACTIVITY DESCRIPTION FACULTY. Opioid Use in Palliative Care. Opioid Analgesic Use in Chronic, Non-cancer Pain
ACTIVITY DESCRIPTION Target Audience This continuing pharmacy education activity is planned to meet the needs of pharmacists in a variety of practice settings, including large and small healthcare systems,
More informationMOVICOL Launched in Japan -The First Polyethylene Glycol Preparation for Chronic Constipation in Japan-
MOVICOL Launched in Japan -The First Polyethylene Glycol Preparation for Chronic Constipation in Japan- This material is an English translation of the press release issued on November 29, 2018 in Japanese,
More informationWilliam D. Chey, MD Professor of Medicine University of Michigan
Evidence-based Treatment Strategies for IBS William D. Chey, MD Professor of Medicine University of Michigan Rome III criteria for IBS Recurrent abdominal pain or discomfort at least 3 days / month in
More informationLinaclotide Improves Abdominal Pain and Bowel Habits in a Phase IIb Study of Patients With Irritable Bowel Syndrome With Constipation
GASTROENTEROLOGY 2010;139:1877 1886 CLINICAL Linaclotide Improves Abdominal Pain and Bowel Habits in a Phase IIb Study of Patients With Irritable Bowel Syndrome With Constipation JEFFREY M. JOHNSTON,*
More informationDrug Evaluation. Use of lubiprostone in constipating disorders and its potential for opioid-induced bowel dysfunction
Use of lubiprostone in constipating disorders and its potential for opioid-induced bowel dysfunction Lubiprostone is a novel medication, approved by the US FDA for the treatment of chronic idiopathic constipation
More informationNEL RISPETTO DELLE NUOVE DISPOSIZIONI IN MATERIA DI ECM, A SEGUITO DELL ATTUAZIONE DELL ACCORDO STATO-REGIONI DEL 5/11/09 E SUCCESSIVE
NOME E NUMERO DEL PROVIDER: I&C SRL - 5387 ECM N : 180726 TITOLO: XVII CONGRESSO NAZIONALE GISMAD SEDE: MILANO, HOTEL NHOW DATA: 09-10/03/2017 NEL RISPETTO DELLE NUOVE DISPOSIZIONI IN MATERIA DI ECM, A
More informationCommon Gastrointestinal Problems in the Elderly
Common Gastrointestinal Problems in the Elderly Brian Viviano, D.O. Objectives Understand the pathophysiology, clinical manifestations, diagnosis and management of GI diseases of the elderly. Differentiate
More informationStudies on inflammatory bowel disease and functional gastrointestinal disorders in children and adults Hoekman, D.R.
UvA-DARE (Digital Academic Repository) Studies on inflammatory bowel disease and functional gastrointestinal disorders in children and adults Hoekman, D.R. Link to publication Citation for published version
More informationDrugs in Development for Opioid-Induced Constipation
7 Drugs in Development for Opioid-Induced Constipation Kelly S. Sprawls, Egilius L.H. Spierings and Dustin Tran MedVadis Research Corporation USA 1. Introduction Opioid-induced bowel dysfunction (OIBD)
More informationIrritable Bowel Syndrome and Chronic Constipation
Title slide - part 1 Irritable Bowel Syndrome and Chronic Constipation IBS - Physiologic Research Stress affects GI function Meals Pain / motility Time Line of Physiologic Research in IBS Pain sensitivit
More informationIBS: overview and assessment of pain outcomes and implications for inclusion criteria
IBS: overview and assessment of pain outcomes and implications for inclusion criteria William D. Chey, MD Professor of Medicine University of Michigan What is the Irritable Bowel Syndrome Symptom based
More information(linzess) for irritable Bowel syndrome With Constipation and For Chronic idiopathic Constipation
DrUG FOrECAST PHarMaCoKiNEtiCs and PHarMaCoDYNaMiCs Linaclotide elicits its pharmacological effects locally in the GI tract with minilinaclotide (linzess) for irritable Bowel syndrome With Constipation
More informationConstipation. H. David Vargas, MD. Overview
Constipation H. David Vargas, MD Overview Constipation is a very common complaint affecting upwards of 15% of all Americans. Fortunately, constipation usually is simple to avoid and easy to treat when
More informationTenapanor for irritable bowel syndrome with constipation
NIHR Innovation Observatory Evidence Briefing: February 2018 Tenapanor for irritable bowel syndrome with constipation NIHRIO (HSRIC) ID: 6704 NICE ID: 9736 LAY SUMMARY Irritable bowel syndrome with constipation
More information효과적인대장정결법 김태준 삼성서울병원소화기내과
효과적인대장정결법 김태준 삼성서울병원소화기내과 부적절한장정결 Efficacy blurring - 긴검사시간 - 낮은맹장도달율 & 선종발견율 Risk intensification - 시술관련합병증증가 Waste of cost - 검사반복 - 내시경의사의 workload 증가 Patient dissatisfaction 장정결에따른선종발견율차이 Multi-centers
More informationTechnology appraisal guidance Published: 22 July 2015 nice.org.uk/guidance/ta345
Naloxegol for treating opioid-induced constipation Technology appraisal guidance Published: 22 July 2015 nice.org.uk/guidance/ta345 NICE 2017. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-ofrights).
More informationTreatment of Constipation in Adults
This Clinical Resource gives subscribers additional insight related to the Recommendations published in April 2017 ~ Resource #330407 Treatment of Constipation in Adults Use this document as a stepwise
More informationDo Probiotics Provide Adequate Relief From Overall Symptoms, Including Abdominal Pain and Bloating, in Adults With Irritable Bowel Syndrome?
Philadelphia College of Osteopathic Medicine DigitalCommons@PCOM PCOM Physician Assistant Studies Student Scholarship Student Dissertations, Theses and Papers 2015 Do Probiotics Provide Adequate Relief
More informationState of the Art: Management of Irritable Bowel Syndrome
ACG/FGS Annual Spring Symposium March 16-18, 2018 Bonita Springs, FL State of the Art: Management of Irritable Bowel Syndrome William D. Chey, MD Professor of Medicine University of Michigan IBS: Rome
More informationNew Tests and Treatments for Dyspepsia and Irritable Bowel Syndrome
New Tests and Treatments for Dyspepsia and Irritable Bowel Syndrome Soojong Hong Chae, MD Clinical Assistant Professor Digestive Diseases and Nutrition University of South Florida ROME III Functional dyspepsia
More informationHorizon Scanning Technology Summary. Methylnaltrexone for opioid induced constipation in advanced illness and palliative care
Horizon Scanning Technology Summary National Horizon Scanning Centre Methylnaltrexone for opioid induced constipation in advanced illness and palliative care April 2007 This technology summary is based
More informationGuidelines NICE, not NICE and the Daily Mail. Dr Andy Poullis Consultant Gastroenterologist
Guidelines NICE, not NICE and the Daily Mail 2018 Dr Andy Poullis Consultant Gastroenterologist Coeliac IBS Gall bladder polyps PEI PPI Who to test for Coeliac persistent unexplained abdominal or gastrointestinal
More informationAmyloidosis & the GI Tract
Amyloidosis & the GI Tract John O. Clarke, M.D. Director, Esophageal Program Clinical Associate Professor of Medicine Stanford University john.clarke@stanford.edu 2017 Topics to cover 1) Patterns of GI
More informationOpioid-Induced Constipation: Update on Prevention and Management EDUCATIONALPROGRAM
EDUCATIONALPROGRAM Recognizing i the Growing Burden of OIC Bill H. McCarberg, MD Founder, Chronic Pain Management Program Kaiser Permanente San Diego Adjunct Assistant Clinical Professor University of
More informationChronic constipation: Update on management
REVIEW CME CREDIT LEARNING OBJECTIVE: Readers will differentiate the types of chronic constipation and apply traditional and newer treatments to best advantage UMAR HAYAT, MD Department of Internal Medicine,
More informationPrimary Management of Irritable Bowel Syndrome
Primary Management of Irritable Bowel Syndrome Jasmine Zia, MD Acting Instructor, Division of Gastroenterology Current Concepts in Drug Therapy CME Course April 23, 2015 Irritable Bowel Syndrome (IBS)
More informationOpioid induced constipation in cancer patients: pathophysiology, diagnosis and treatment
Expert Review of Quality of Life in Cancer Care ISSN: (Print) 2380-9000 (Online) Journal homepage: http://www.tandfonline.com/loi/terq20 Opioid induced constipation in cancer patients: pathophysiology,
More informationpissn: eissn: Journal of Neurogastroenterology and Motility
JNM J Neurogastroenterol Motil, Vol. 20 No. 3 July, 2014 pissn: 2093-0879 eissn: 2093-0887 http://dx.doi.org/10.5056/jnm14022 Original Article Effects of Chili Treatment on Gastrointestinal and Rectal
More informationChronic Abdominal Pain. Dr. Robert B. Smith Tupelo Digestive Health Specialists August 26, 2016
Chronic Abdominal Pain Dr. Robert B. Smith Tupelo Digestive Health Specialists August 26, 2016 Disclosures Speaker Bureau for Allergan Pharmaceuticals Abdominal Pain - Definitions Acute occurring for several
More informationImproving the Diagnosis and Management of Opioid-induced Constipation to Optimize Outcomes of Patients with Chronic Pain
Improving the Diagnosis and Management of Opioid-induced Constipation to Optimize Outcomes of Patients with Chronic Pain Sponsored by Integrity Continuing Education, Inc. Supported by an educational grant
More informationDOCTOR DISCUSSION GUIDE
What your doctor needs to know To make your appointment more productive, share this completed guide with your doctor. That way, he or she can recommend an appropriate treatment plan for you. Check the
More informationOur evidence. Your expertise. SmartPill : The data you need to evaluate motility disorders.
Our evidence. Your expertise. SmartPill : The data you need to evaluate motility disorders. SmartPill benefits your practice: Convenient performed right in your office Test standardization Provides direct
More information